Androbiosys, Inc.
- UEI
- P2WARTHHE274
- CAGE
- 4TPC1
- Primary NAICS
- 541711 Research and Development in Biotechnology
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- conductscience.com
- Founded
- 2013
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 38 Instruments & Related Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Definitive Contract HHSN261201000119C | National Cancer Institute (NIH) | $999,326 | |
| Sbir topic 241: platelet-based nanoparticle therapy for prostate cancer | National Cancer Institute (NIH) | $149,994 | |
| Sttr phase i | Medical Command (Army) | $844,318 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Primary xenografts of human tissue as surrogates of cancer in situ | National Institutes of Health | $139,945 | |
| Vascular targeting for imaging and treatment of benign prostatic hyperplasia | National Institutes of Health | $128,052 |
Quick answers
Is Androbiosys, Inc. registered in SAM.gov?
Androbiosys, Inc.'s SAM.gov registration expired on October 18, 2014.
What is Androbiosys, Inc.'s most recent federal award?
Androbiosys, Inc.'s most recent federal contract award is Definitive Contract HHSN261201000119C, from National Cancer Institute (NIH), on September 30, 2010.
On GovTribe
See Androbiosys, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors